Precision Medicine in Graves’ Disease: CD40 Gene Variants Predict Clinical Response to an Anti-CD40 Monoclonal Antibody

BACKGROUND: CD40, a key co-stimulatory molecule expressed on antigen-presenting cells, is genetically associated with a number of autoimmune diseases including Graves’ disease (GD). Therefore, recent therapies targeting CD40 have been developed, including the anti-CD40 monoclonal antibody Iscalimab....

Descripción completa

Detalles Bibliográficos
Autores principales: Faustino, Larissa C., Kahaly, George J., Frommer, Lara, Concepcion, Erlinda, Stefan-Lifshitz, Mihaela, Tomer, Yaron
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8212124/
https://www.ncbi.nlm.nih.gov/pubmed/34149627
http://dx.doi.org/10.3389/fendo.2021.691781

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8212124/
https://www.ncbi.nlm.nih.gov/pubmed/34149627
http://dx.doi.org/10.3389/fendo.2021.691781

Ejemplares similares